Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care
Aim<br> To identify people in English primary care with equivalent cardiovascular risk to participants in the sodium–glucose co‐transporter‐2 inhibitor (SGLT‐2i) cardiovascular outcome trials (CVOTs). A secondary objective was to report the usage of SGLT‐2is. <br><br> Methods<br...
Main Authors: | Hinton, W, Feher, M, Munro, N, Joy, M, de Lusignan, S |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Wiley
2020
|
Similar Items
-
How generalizable are cardiovascular outcome trials of sodium-glucose co-transporter-2 inhibitors? A national database study: study protocol
by: Hinton, W, et al.
Published: (2019) -
Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis
by: Hinton, W, et al.
Published: (2021) -
Does renal function or heart failure diagnosis affect primary care prescribing for sodium-Glucose co-transporter 2 inhibitors in type 2 diabetes?
by: Hinton, W, et al.
Published: (2020) -
A comparison of sodium-glucose co-transporter 2 inhibitor kidney outcome trial participants with a real-world chronic kidney disease primary care population
by: Forbes, AK, et al.
Published: (2024) -
Sodium-glucose co-transporter 2 (SGLT2) inhibitor: comparing trial data and real-world use
by: McGovern, A, et al.
Published: (2017)